<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-B2K2G48T/f54df15c-b648-4433-a406-b557b43a3045/PDF"><dcterms:extent>171 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-B2K2G48T/2e712ab2-5e6b-4060-86f2-ebb2b5e54f52/TEXT"><dcterms:extent>33 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-B2K2G48T/1af4f88f-6225-4001-b382-cfdf9964037f/PDF"><dcterms:extent>135 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-B2K2G48T/d0ed2847-b279-4ab1-b319-d482e053a7e9/TEXT"><dcterms:extent>33 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-B2K2G48T"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2021</dcterms:issued><dc:creator>Barbarić Kovačić, Aleksandra</dc:creator><dc:creator>Stanišić, Slavica</dc:creator><dc:creator>Zver, Samo</dc:creator><dc:format xml:lang="sl">številka:3/4</dc:format><dc:format xml:lang="sl">letnik:90</dc:format><dc:format xml:lang="sl">str. 193-201</dc:format><dc:identifier>DOI:10.6016/ZdravVestn.3009</dc:identifier><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:69507587</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-B2K2G48T</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="en">blood components</dc:subject><dc:subject xml:lang="en">irradiation</dc:subject><dc:subject xml:lang="sl">krvni pripravki</dc:subject><dc:subject xml:lang="sl">obsevanje z ionizirajočimi žarki</dc:subject><dc:subject xml:lang="sl">TA-GvHD</dc:subject><dc:subject xml:lang="sl">transfuzija</dc:subject><dc:subject xml:lang="sl">zapleti</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Reakcija presadka proti gostitelju po transfuziji krvi in kako jo preprečimo| Transfusion associated graft vs. host disease and how to prevent it|</dc:title><dc:description xml:lang="sl">Transfusion associated graft versus host disease (TA-GvHD) is a rare but fatal complication of blood components transfusion therapy and has over 90% mortality rate. Transfused donor T lymphocytes react against the recipient's cellular and tissue antigens. Interaction triggers lymphocyte activation and, consequently, destruction of target cells in the recipient's tissues . The reason that immune cells of the recipient do not respond appropriately is an incompetent recipient's immune system and immunodeficiency of the host. Exceptionally, HLA compatibility between the donor and the recipient may cause the same reaction. Most effective way to prevent TA-GvHD is irradiation of the blood components with ionizing radiation. UVA psoralen based pathogen inactivation is an equally effective preventive measure of TA-GvHD, but it is applicable only to platelets. For this reason, it is important that physicians identify patients at risk of developing TA-GvHD and consequentially always prescribe irradiated blood units. Blood units that need to be irradiated are erythrocytes and granulocytes, with the mentioned exception of platelets. Fresh frozen plasma, cryoprecipitate, blood derived medicines, such as albumins, immunoglobulins, blood clotting factors, and erythrocytes after thawing are not irradiated. The recommended central field irradiation dose is 25-50 Gy</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-B2K2G48T"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-B2K2G48T" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-B2K2G48T/f54df15c-b648-4433-a406-b557b43a3045/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-B2K2G48T/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-B2K2G48T" /></ore:Aggregation></rdf:RDF>